Pub Date : 2026-03-01Epub Date: 2026-02-28DOI: 10.1016/j.jvsv.2025.102414
Mateo Coppola BS , Justin Wang BA , James Whitley BS , Ethan Chi BS , Estefania Narvaez BS , Michelle Antony BS , Eric Hager MD
{"title":"Outcomes and Economic Impact of Ultrasound Evaluation to Rule Out Deep Vein Thrombosis in a Multihospital Health System","authors":"Mateo Coppola BS , Justin Wang BA , James Whitley BS , Ethan Chi BS , Estefania Narvaez BS , Michelle Antony BS , Eric Hager MD","doi":"10.1016/j.jvsv.2025.102414","DOIUrl":"10.1016/j.jvsv.2025.102414","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 2","pages":"Article 102414"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147396088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-28DOI: 10.1016/j.jvsv.2025.102409
Anusha Jacob DO
{"title":"Nitinol Venous Stents Do Not Improve Iliac Vein Stenting Accuracy in Comparison to Elgiloy Stents","authors":"Anusha Jacob DO","doi":"10.1016/j.jvsv.2025.102409","DOIUrl":"10.1016/j.jvsv.2025.102409","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 2","pages":"Article 102409"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147395620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Observation of Bidirectional Lymph Flow Dynamics at the Dermal Backflow Areas in Lymphedema Using Contrast-enhanced Ultrasound","authors":"Takahiro Hirayama MD , Kiyoka Omoto MD, PhD , Shinobu Matsubara MD, PhD , Naoto Yamamoto MD, PhD","doi":"10.1016/j.jvsv.2025.102412","DOIUrl":"10.1016/j.jvsv.2025.102412","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 2","pages":"Article 102412"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147396077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-28DOI: 10.1016/j.jvsv.2025.102423
Joseph Hart MD, MHL , Mona Li MD , Mark Davies MD, PhD, MBA
{"title":"Risk Activity Index: A Measure of Frailty and Its Impact on Venous Leg Ulcer Healing and Recurrence","authors":"Joseph Hart MD, MHL , Mona Li MD , Mark Davies MD, PhD, MBA","doi":"10.1016/j.jvsv.2025.102423","DOIUrl":"10.1016/j.jvsv.2025.102423","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 2","pages":"Article 102423"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147396149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-01-05DOI: 10.1016/j.jvsv.2025.102441
Binyu Zheng MS , Yangzheng Xia MS , Ranting Ye MS , Dongmei Liu MD, PhD , Gaorui Liu AMS, FASA, RPhS , Yong Liu MD, PhD
<div><h3>Objective</h3><div>The study aims to elucidate the factors associated with the short-term efficacy of ovarian vein embolization (OVE) in the treatment of pelvic venous insufficiency (PVI), to construct a predictive model for short-term efficacy of OVE.</div></div><div><h3>Methods</h3><div>Clinical and ultrasound data were retrospectively collected from female patients with PVI and underwent OVE at Beijing Shijitan Hospital between January 2019 and February 2025. This study used the minimal clinically important difference to define symptomatic improvement in the Pelvic Venous Clinical Severity Score. Symptomatic improvement was used as the evaluation criterion, and the related factors affecting the short-term efficacy were analyzed. The receiver operating characteristic curve was also applied to assess the predictive efficacy of the model and calculate the optimal efficiency cut-off value. Internal validation was performed using k-fold cross-validation to assess discrimination, calibration, and clinical utility.</div></div><div><h3>Results</h3><div>The study included a total of 82 patients: 43 patients in the remission group and 39 patients in the nonremission group. No statistically significant differences were found between the two groups with regard to age, body mass index, history of abortion, history of varicose veins of the lower extremities, the number of pregnancies and deliveries. The duration of lower abdominal discomfort in the nonremission group was longer than that in the remission group (<em>t</em> = −1.713; <em>P</em> = .004; independent samples <em>t</em> test). Transabdominal ultrasound showed that the diameter of the left ovarian vein (OV) in the nonremission group was smaller (<em>Z</em> = −2.958; <em>P</em> = .003; Mann-Whitney <em>U</em> test), and the diameter of the left parametrial vein in the nonremission group was smaller (<em>Z</em> = −2.494; <em>P</em> = .013). In addition, the positive rate of internal iliac vein reflux in the nonremission group was higher (χ<sup>2</sup> = 15.649; <em>P</em> < .001; χ<sup>2</sup> test or Fisher's exact test). Binary logistic regression analysis showed that the longer the duration of lower abdominal discomfort (odds ratio [OR], 1.115; 95% confidence interval [CI], 1.001-1.332; <em>P</em> = .049), the smaller the diameter of the left OV (OR, 0.669; 95% CI,0.483-0.928; <em>P</em> = .016) and internal iliac vein reflux (OR, 6.449; 95% CI, 2.238-15.583; <em>P</em> < .001) were independent risk factors for the short-term efficacy of OVE for PVI. The area under the receiver operating characteristic curve (AUC) was 0.807 (95% CI, 0.712-0.902), and the best cut-off value was 0.453. The sensitivity and specificity of predicting the short-term efficacy of OVE were 82.1% and 74.4%, respectively. Internal validation showed acceptable discrimination (area under the receiver operating characteristic curve = 0.779), a Brier score of 0.176 indicating adequate accuracy, reasonable calibra
{"title":"Analysis of factors influencing the efficacy of ovarian vein embolization for pelvic venous insufficiency and development of a short-term efficacy prediction model with internal validation","authors":"Binyu Zheng MS , Yangzheng Xia MS , Ranting Ye MS , Dongmei Liu MD, PhD , Gaorui Liu AMS, FASA, RPhS , Yong Liu MD, PhD","doi":"10.1016/j.jvsv.2025.102441","DOIUrl":"10.1016/j.jvsv.2025.102441","url":null,"abstract":"<div><h3>Objective</h3><div>The study aims to elucidate the factors associated with the short-term efficacy of ovarian vein embolization (OVE) in the treatment of pelvic venous insufficiency (PVI), to construct a predictive model for short-term efficacy of OVE.</div></div><div><h3>Methods</h3><div>Clinical and ultrasound data were retrospectively collected from female patients with PVI and underwent OVE at Beijing Shijitan Hospital between January 2019 and February 2025. This study used the minimal clinically important difference to define symptomatic improvement in the Pelvic Venous Clinical Severity Score. Symptomatic improvement was used as the evaluation criterion, and the related factors affecting the short-term efficacy were analyzed. The receiver operating characteristic curve was also applied to assess the predictive efficacy of the model and calculate the optimal efficiency cut-off value. Internal validation was performed using k-fold cross-validation to assess discrimination, calibration, and clinical utility.</div></div><div><h3>Results</h3><div>The study included a total of 82 patients: 43 patients in the remission group and 39 patients in the nonremission group. No statistically significant differences were found between the two groups with regard to age, body mass index, history of abortion, history of varicose veins of the lower extremities, the number of pregnancies and deliveries. The duration of lower abdominal discomfort in the nonremission group was longer than that in the remission group (<em>t</em> = −1.713; <em>P</em> = .004; independent samples <em>t</em> test). Transabdominal ultrasound showed that the diameter of the left ovarian vein (OV) in the nonremission group was smaller (<em>Z</em> = −2.958; <em>P</em> = .003; Mann-Whitney <em>U</em> test), and the diameter of the left parametrial vein in the nonremission group was smaller (<em>Z</em> = −2.494; <em>P</em> = .013). In addition, the positive rate of internal iliac vein reflux in the nonremission group was higher (χ<sup>2</sup> = 15.649; <em>P</em> < .001; χ<sup>2</sup> test or Fisher's exact test). Binary logistic regression analysis showed that the longer the duration of lower abdominal discomfort (odds ratio [OR], 1.115; 95% confidence interval [CI], 1.001-1.332; <em>P</em> = .049), the smaller the diameter of the left OV (OR, 0.669; 95% CI,0.483-0.928; <em>P</em> = .016) and internal iliac vein reflux (OR, 6.449; 95% CI, 2.238-15.583; <em>P</em> < .001) were independent risk factors for the short-term efficacy of OVE for PVI. The area under the receiver operating characteristic curve (AUC) was 0.807 (95% CI, 0.712-0.902), and the best cut-off value was 0.453. The sensitivity and specificity of predicting the short-term efficacy of OVE were 82.1% and 74.4%, respectively. Internal validation showed acceptable discrimination (area under the receiver operating characteristic curve = 0.779), a Brier score of 0.176 indicating adequate accuracy, reasonable calibra","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 2","pages":"Article 102441"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-12-29DOI: 10.1016/j.jvsv.2025.102440
Karissa M. Wang MD, Blake E. Murphy MD, Jake F. Hemingway MD
<div><h3>Objective</h3><div>Inferior vena cava (IVC) occlusion resulting from deep vein thrombosis (DVT) or embryologic developmental abnormalities can result in debilitating symptoms, including lower extremity pain, edema, and venous ulceration. This study describes the outcomes associated with endovascular recanalization and stenting of chronic IVC occlusions with dedicated venous nitinol stents.</div></div><div><h3>Methods</h3><div>Patients who underwent endovascular recanalization and nitinol venous stenting at a single institution from 2022 to 2025 were identified. Demographics, comorbidities, CEAP classification, venous reconstruction details, and outcomes, including symptomatic improvement and 30-day complications, were collected. Descriptive analysis was completed. Primary and secondary patency was assessed using Kaplan-Meier analysis.</div></div><div><h3>Results</h3><div>A total of 22 patients with symptomatic IVC occlusions underwent attempted recanalization. The median age at the time of treatment was 41 years (interquartile range [IQR], 37-71 years), and patients were predominantly male (77%). Patient comorbidities included active tobacco use (55%), hypertension (41%), and hypercoagulable disorders (32%). On presentation, 20 patients (91%) had post-thrombotic syndrome, 12 (55%) had CEAP class 4 to 6 chronic venous disease, six (27%) had occluded IVC filters, four (18%) had a prior failed venous intervention, and five (23%) had chronic stent occlusions. The etiology of chronic IVC occlusion included DVT in 13 patients (59%), IVC filter-associated thrombosis in four patients (18%), surgical-related IVC stenosis in two patients (9%), congenital abnormalities in two patients (9%), and IVC clipping in one patient (5%). Cranial extent of stenting was infrarenal in 11 patients (52%) and suprarenal in 10 patients (48%). Common femoral veins were stented in 27 patients (64% of limbs). Sharp recanalization was required in three patients (14%). A total of 21 patients (95%) achieved technical success. All patients were anticoagulated postoperatively, and the median length of stay was 1 day (IQR, 0-2 days). Two patients (9.5%) experienced bleeding-related complications within 30 days. The median follow-up was 259 days (IQR, 78-473 days). Primary patency for the IVC stents was 100% at 12 months. Primary and secondary patency for all components within the venous reconstruction, including IVC and iliofemoral stents, was 84% and 100% at 1 year, respectively. All patients reported symptomatic improvement and venous ulcers healing (if present at index presentation) within 1 year following intervention.</div></div><div><h3>Conclusions</h3><div>Treatment of chronic IVC occlusions using dedicated venous nitinol stents is safe with excellent midterm patency and symptom improvement at 1 year postoperatively. Multi-institutional studies with larger patient populations and standardized outcomes, including quality of life and cost measures, are required to furt
{"title":"Results of dedicated venous nitinol stents in treating chronic inferior vena cava occlusions","authors":"Karissa M. Wang MD, Blake E. Murphy MD, Jake F. Hemingway MD","doi":"10.1016/j.jvsv.2025.102440","DOIUrl":"10.1016/j.jvsv.2025.102440","url":null,"abstract":"<div><h3>Objective</h3><div>Inferior vena cava (IVC) occlusion resulting from deep vein thrombosis (DVT) or embryologic developmental abnormalities can result in debilitating symptoms, including lower extremity pain, edema, and venous ulceration. This study describes the outcomes associated with endovascular recanalization and stenting of chronic IVC occlusions with dedicated venous nitinol stents.</div></div><div><h3>Methods</h3><div>Patients who underwent endovascular recanalization and nitinol venous stenting at a single institution from 2022 to 2025 were identified. Demographics, comorbidities, CEAP classification, venous reconstruction details, and outcomes, including symptomatic improvement and 30-day complications, were collected. Descriptive analysis was completed. Primary and secondary patency was assessed using Kaplan-Meier analysis.</div></div><div><h3>Results</h3><div>A total of 22 patients with symptomatic IVC occlusions underwent attempted recanalization. The median age at the time of treatment was 41 years (interquartile range [IQR], 37-71 years), and patients were predominantly male (77%). Patient comorbidities included active tobacco use (55%), hypertension (41%), and hypercoagulable disorders (32%). On presentation, 20 patients (91%) had post-thrombotic syndrome, 12 (55%) had CEAP class 4 to 6 chronic venous disease, six (27%) had occluded IVC filters, four (18%) had a prior failed venous intervention, and five (23%) had chronic stent occlusions. The etiology of chronic IVC occlusion included DVT in 13 patients (59%), IVC filter-associated thrombosis in four patients (18%), surgical-related IVC stenosis in two patients (9%), congenital abnormalities in two patients (9%), and IVC clipping in one patient (5%). Cranial extent of stenting was infrarenal in 11 patients (52%) and suprarenal in 10 patients (48%). Common femoral veins were stented in 27 patients (64% of limbs). Sharp recanalization was required in three patients (14%). A total of 21 patients (95%) achieved technical success. All patients were anticoagulated postoperatively, and the median length of stay was 1 day (IQR, 0-2 days). Two patients (9.5%) experienced bleeding-related complications within 30 days. The median follow-up was 259 days (IQR, 78-473 days). Primary patency for the IVC stents was 100% at 12 months. Primary and secondary patency for all components within the venous reconstruction, including IVC and iliofemoral stents, was 84% and 100% at 1 year, respectively. All patients reported symptomatic improvement and venous ulcers healing (if present at index presentation) within 1 year following intervention.</div></div><div><h3>Conclusions</h3><div>Treatment of chronic IVC occlusions using dedicated venous nitinol stents is safe with excellent midterm patency and symptom improvement at 1 year postoperatively. Multi-institutional studies with larger patient populations and standardized outcomes, including quality of life and cost measures, are required to furt","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 2","pages":"Article 102440"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145878051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-11-29DOI: 10.1016/j.jvsv.2025.102359
Laurens A. Oomen MD, MSc , Janette van Diest BSc , Felice R.M. Lucas BSc , Jitske Rijpkema MD , George L. Burchell MSc , Florianne J.L. van Zanten MD , Kee F. Choi MD , Marcella C.A. Muller MD, PhD , Angelique M.E. de Man MD, MSc, PhD , Alexander P.J. Vlaar MD, PhD, MBA , Jarom Heijmans MD, PhD , Bart J. Biemond MD, PhD , Nick van Es MD, PhD , Jasper M. Smit MD, PhD , Pieter R. Tuinman MD, PhD
Background
Catheter-related thrombosis (CRT) is a known complication of central venous catheters and peripherally inserted central catheters, yet optimal treatment remains uncertain. We conducted a systematic review and national survey to assess current CRT management strategies.
Methods
Following the PRISMA guidelines, we searched three databases through October 2024 for studies on CRT associated with central venous catheters or peripherally inserted central catheters. Meta-analyses and subgroup analyses were performed by anticoagulant type. A national survey among Dutch intensive care and hematology physicians explored current treatment practices.
Results
Of 4123 records screened, 34 observational studies were included, mostly involving patients with cancer. The venous thromboembolism recurrence rate per 100 patient-years was higher in patients with cancer (14.1; 95% confidence interval, 11.4- 17.4; I2 = 35.1) vs patients without cancer (2.0; 95% confidence interval, 0.6-6.0; I2 = 10.3; P = .0002). Recurrence was comparable between direct oral anticoagulants (DOACs) and low-molecular-weight heparin/vitamin K antagonists (LMWH/VKAs), at 11.0 vs 7.6 (P = .14). Major bleeding occurred in 10.5 vs 13.1 (P = .45), and clinically relevant nonmajor bleeding in 26.2 vs. 22.4 (P = .70), for DOACs vs LMWH/VKAs, respectively. All studies were observational, most at high risk of bias. Survey data showed LMWH was preferred for symptomatic CRT (50%), with treatment lasting 8 days to 6 months. In asymptomatic CRT, anticoagulant type and duration were left to physician discretion in 64% of cases.
Conclusions
Treatment with LMWH/VKA or DOACs shows similarly low venous thromboembolism recurrence, although rates are higher in patients with cancer. Bleeding was substantial and comparable across therapies. Evidence is limited by observational bias. Survey data show that LMWH predominates for CRT, with variable duration. Well-designed randomized controlled trials are warranted.
{"title":"Treatment of catheter related thrombosis: A systematic review, meta-analysis, and national survey","authors":"Laurens A. Oomen MD, MSc , Janette van Diest BSc , Felice R.M. Lucas BSc , Jitske Rijpkema MD , George L. Burchell MSc , Florianne J.L. van Zanten MD , Kee F. Choi MD , Marcella C.A. Muller MD, PhD , Angelique M.E. de Man MD, MSc, PhD , Alexander P.J. Vlaar MD, PhD, MBA , Jarom Heijmans MD, PhD , Bart J. Biemond MD, PhD , Nick van Es MD, PhD , Jasper M. Smit MD, PhD , Pieter R. Tuinman MD, PhD","doi":"10.1016/j.jvsv.2025.102359","DOIUrl":"10.1016/j.jvsv.2025.102359","url":null,"abstract":"<div><h3>Background</h3><div>Catheter-related thrombosis (CRT) is a known complication of central venous catheters and peripherally inserted central catheters, yet optimal treatment remains uncertain. We conducted a systematic review and national survey to assess current CRT management strategies.</div></div><div><h3>Methods</h3><div>Following the PRISMA guidelines, we searched three databases through October 2024 for studies on CRT associated with central venous catheters or peripherally inserted central catheters. Meta-analyses and subgroup analyses were performed by anticoagulant type. A national survey among Dutch intensive care and hematology physicians explored current treatment practices.</div></div><div><h3>Results</h3><div>Of 4123 records screened, 34 observational studies were included, mostly involving patients with cancer. The venous thromboembolism recurrence rate per 100 patient-years was higher in patients with cancer (14.1; 95% confidence interval, 11.4- 17.4; I<sup>2</sup> = 35.1) vs patients without cancer (2.0; 95% confidence interval, 0.6-6.0; I<sup>2</sup> = 10.3; <em>P</em> = .0002). Recurrence was comparable between direct oral anticoagulants (DOACs) and low-molecular-weight heparin/vitamin K antagonists (LMWH/VKAs), at 11.0 vs 7.6 (<em>P</em> = .14). Major bleeding occurred in 10.5 vs 13.1 (<em>P</em> = .45), and clinically relevant nonmajor bleeding in 26.2 vs. 22.4 (<em>P</em> = .70), for DOACs vs LMWH/VKAs, respectively. All studies were observational, most at high risk of bias. Survey data showed LMWH was preferred for symptomatic CRT (50%), with treatment lasting 8 days to 6 months. In asymptomatic CRT, anticoagulant type and duration were left to physician discretion in 64% of cases.</div></div><div><h3>Conclusions</h3><div>Treatment with LMWH/VKA or DOACs shows similarly low venous thromboembolism recurrence, although rates are higher in patients with cancer. Bleeding was substantial and comparable across therapies. Evidence is limited by observational bias. Survey data show that LMWH predominates for CRT, with variable duration. Well-designed randomized controlled trials are warranted.</div></div>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 2","pages":"Article 102359"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145648894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-28DOI: 10.1016/j.jvsv.2026.102458
{"title":"Erratum.","authors":"","doi":"10.1016/j.jvsv.2026.102458","DOIUrl":"10.1016/j.jvsv.2026.102458","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102458"},"PeriodicalIF":2.8,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147307296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：